Y Intercept Hong Kong Ltd Takes Position in NeuroPace, Inc. $NPCE

Y Intercept Hong Kong Ltd bought a new stake in shares of NeuroPace, Inc. (NASDAQ:NPCE) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 53,894 shares of the company’s stock, valued at approximately $600,000. Y Intercept Hong Kong Ltd owned 0.16% of NeuroPace at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. HighMark Wealth Management LLC boosted its stake in shares of NeuroPace by 2,000.0% during the second quarter. HighMark Wealth Management LLC now owns 63,000 shares of the company’s stock valued at $702,000 after purchasing an additional 60,000 shares during the period. First Light Asset Management LLC purchased a new stake in shares of NeuroPace during the first quarter valued at $19,468,000. Ghisallo Capital Management LLC purchased a new stake in shares of NeuroPace during the first quarter valued at $2,458,000. Palumbo Wealth Management LLC boosted its stake in shares of NeuroPace by 268.4% during the second quarter. Palumbo Wealth Management LLC now owns 169,890 shares of the company’s stock valued at $1,893,000 after purchasing an additional 123,779 shares during the period. Finally, Lord Abbett & CO. LLC purchased a new stake in shares of NeuroPace during the first quarter valued at $5,727,000. 78.83% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of NeuroPace in a research note on Wednesday, October 8th. JPMorgan Chase & Co. lifted their price objective on NeuroPace from $16.00 to $18.00 and gave the company an “overweight” rating in a report on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $16.00 price objective on shares of NeuroPace in a research note on Wednesday. Wells Fargo & Company upped their price objective on shares of NeuroPace from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Wednesday. Finally, Leerink Partners reaffirmed an “outperform” rating and issued a $19.00 price objective on shares of NeuroPace in a research note on Wednesday. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $17.33.

NeuroPace Stock Performance

Shares of NeuroPace stock opened at $12.98 on Thursday. The company has a market capitalization of $429.38 million, a PE ratio of -17.08 and a beta of 1.90. The company has a debt-to-equity ratio of 3.02, a quick ratio of 4.51 and a current ratio of 5.47. The company has a 50-day simple moving average of $10.21 and a two-hundred day simple moving average of $10.84. NeuroPace, Inc. has a one year low of $6.63 and a one year high of $18.98.

NeuroPace (NASDAQ:NPCE) last announced its earnings results on Tuesday, November 4th. The company reported ($0.11) EPS for the quarter, topping analysts’ consensus estimates of ($0.20) by $0.09. The business had revenue of $27.35 million during the quarter, compared to the consensus estimate of $24.64 million. NeuroPace had a negative net margin of 25.28% and a negative return on equity of 139.13%. NeuroPace has set its FY 2025 guidance at EPS. Research analysts expect that NeuroPace, Inc. will post -1 EPS for the current fiscal year.

NeuroPace Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.